GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Asset Turnover

BLAC (Bellevue Life Sciences Acquisition) Asset Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bellevue Life Sciences Acquisition's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Bellevue Life Sciences Acquisition's Total Assets for the quarter that ended in Sep. 2024 was $20.78 Mil. Therefore, Bellevue Life Sciences Acquisition's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Bellevue Life Sciences Acquisition's annualized ROE % for the quarter that ended in Sep. 2024 was -6.15%. It is also linked to ROA % through Du Pont Formula. Bellevue Life Sciences Acquisition's annualized ROA % for the quarter that ended in Sep. 2024 was -4.45%.


Bellevue Life Sciences Acquisition Asset Turnover Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Asset Turnover Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - -

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellevue Life Sciences Acquisition's Asset Turnover

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's Asset Turnover Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Asset Turnover falls into.



Bellevue Life Sciences Acquisition Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bellevue Life Sciences Acquisition's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (1.226+36.628)/ 2 )
=0/18.927
=0.00

Bellevue Life Sciences Acquisition's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (20.634+20.926)/ 2 )
=0/20.78
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bellevue Life Sciences Acquisition  (NAS:BLAC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bellevue Life Sciences Acquisition's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-0.924/15.0305
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.924 / 0)*(0 / 20.78)*(20.78/ 15.0305)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.3825
=ROA %*Equity Multiplier
=-4.45 %*1.3825
=-6.15 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bellevue Life Sciences Acquisition's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-0.924/20.78
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.924 / 0)*(0 / 20.78)
=Net Margin %*Asset Turnover
= %*0
=-4.45 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bellevue Life Sciences Acquisition Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004